Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $4,464.0M | $3,951.0M | $2,621.0M | $3,528.0M | $4,241.0M | $5,738.0M | $5,605.0M | $6,647.0M | $3,932.0M | $2,931.0M | $1,714.0M | $1,730.0M | $4,539.0M | $3,450.0M | $5,118.0M | $5,464.0M | $5,128.0M | $10.2B | $10.3B | $17.2B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Bristol-Myers Squibb Company's last 12-month Operating Income is $10.3B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Bristol-Myers Squibb Company's Operating Income growth was (24.1%). The average annual Operating Income growth rates for Bristol-Myers Squibb Company have been 13.5% over the past three years, 13.6% over the past five years.
Over the last year, Bristol-Myers Squibb Company's Operating Income growth was (24.1%), which is lower than industry growth of 0.0%. It indicates that Bristol-Myers Squibb Company's Operating Income growth is Bad.